pharmaobservatory 0.1.13 → 0.1.15

This diff represents the content of publicly available package versions that have been released to one of the supported registries. The information contained in this diff is provided for informational purposes only and reflects changes between package versions as they appear in their respective public registries.
Files changed (47) hide show
  1. checksums.yaml +4 -4
  2. data/README.md +25 -5
  3. data/docs/BiomarkerValidationRow.md +1 -1
  4. data/docs/ChangesList200Response.md +26 -0
  5. data/docs/ChangesList200ResponseBuildState.md +20 -0
  6. data/docs/ChangesList200ResponseItemsInner.md +48 -0
  7. data/docs/ChangesList200ResponseItemsInnerEntryKeys.md +18 -0
  8. data/docs/CompaniesApi.md +86 -4
  9. data/docs/CompanyAssetCollisionsResponse.md +58 -0
  10. data/docs/CompanyAssetCollisionsRow.md +68 -0
  11. data/docs/CompanyCompetitorsRow.md +16 -32
  12. data/docs/CompanyFinancialsRow.md +18 -0
  13. data/docs/ConditionAdverseEventsRow.md +5 -1
  14. data/docs/SubscriptionsApi.md +282 -0
  15. data/docs/SubscriptionsCreate201Response.md +22 -0
  16. data/docs/SubscriptionsCreate201ResponseSubscription.md +28 -0
  17. data/docs/SubscriptionsCreate201ResponseSubscriptionTarget.md +22 -0
  18. data/docs/SubscriptionsCreateRequest.md +20 -0
  19. data/docs/SubscriptionsDelete200Response.md +24 -0
  20. data/docs/SubscriptionsList200Response.md +22 -0
  21. data/docs/SubscriptionsList200ResponseSubscriptionsInner.md +28 -0
  22. data/docs/SubscriptionsList200ResponseSubscriptionsInnerTarget.md +26 -0
  23. data/docs/SubscriptionsList200ResponseSubscriptionsInnerTargetFilters.md +18 -0
  24. data/lib/pharmaobservatory/api/companies_api.rb +93 -2
  25. data/lib/pharmaobservatory/api/subscriptions_api.rb +261 -0
  26. data/lib/pharmaobservatory/models/biomarker_validation_row.rb +1 -1
  27. data/lib/pharmaobservatory/models/changes_list200_response.rb +343 -0
  28. data/lib/pharmaobservatory/models/changes_list200_response_build_state.rb +263 -0
  29. data/lib/pharmaobservatory/models/changes_list200_response_items_inner.rb +627 -0
  30. data/lib/pharmaobservatory/models/changes_list200_response_items_inner_entry_keys.rb +237 -0
  31. data/lib/pharmaobservatory/models/company_asset_collisions_response.rb +478 -0
  32. data/lib/pharmaobservatory/models/company_asset_collisions_row.rb +502 -0
  33. data/lib/pharmaobservatory/models/company_competitors_row.rb +61 -153
  34. data/lib/pharmaobservatory/models/company_financials_row.rb +100 -1
  35. data/lib/pharmaobservatory/models/condition_adverse_events_row.rb +27 -5
  36. data/lib/pharmaobservatory/models/subscriptions_create201_response.rb +289 -0
  37. data/lib/pharmaobservatory/models/subscriptions_create201_response_subscription.rb +369 -0
  38. data/lib/pharmaobservatory/models/subscriptions_create201_response_subscription_target.rb +289 -0
  39. data/lib/pharmaobservatory/models/subscriptions_create_request.rb +263 -0
  40. data/lib/pharmaobservatory/models/subscriptions_delete200_response.rb +315 -0
  41. data/lib/pharmaobservatory/models/subscriptions_list200_response.rb +291 -0
  42. data/lib/pharmaobservatory/models/subscriptions_list200_response_subscriptions_inner.rb +369 -0
  43. data/lib/pharmaobservatory/models/subscriptions_list200_response_subscriptions_inner_target.rb +277 -0
  44. data/lib/pharmaobservatory/models/subscriptions_list200_response_subscriptions_inner_target_filters.rb +237 -0
  45. data/lib/pharmaobservatory/version.rb +1 -1
  46. data/lib/pharmaobservatory.rb +16 -0
  47. metadata +34 -2
@@ -14,7 +14,7 @@ require 'date'
14
14
  require 'time'
15
15
 
16
16
  module PharmaObservatory
17
- # One row of the company_competitors dataset: one row per ordered company pair: a company and one of the top 25 companies of each competitor_class by program overlap. A grouped request returns the group columns and the measures instead, as additional properties.
17
+ # One row of the company_competitors dataset: one row per ordered company pair: a company and one of the top 25 companies of each competitor_class by asset collision. A grouped request returns the group columns and the measures instead, as additional properties.
18
18
  class CompanyCompetitorsRow
19
19
  # Company level: the company the row is about; the entry key for the companies object type.
20
20
  attr_accessor :company_id
@@ -43,59 +43,35 @@ module PharmaObservatory
43
43
  # The competitor's class: industry, or non_industry (not classed as industry by the sponsor-class rule: academic, hospital, government, nonprofit, and any record the rule does not reach). competitor_rank restarts at 1 within each class, so filter or sort on this column first.
44
44
  attr_accessor :competitor_class
45
45
 
46
- # How many companies of this competitor_class were candidates (a shared target, or an indication overlap above the similarity floor) before the top 25 were kept. The same value on every row of one company and class.
46
+ # How many companies of this competitor_class had at least one asset collision with the company before the top 25 were kept. The same value on every row of one company and class.
47
47
  attr_accessor :n_class_candidates
48
48
 
49
49
  # The competitor's rank within its competitor_class for the company by competitor_score (1 is the highest).
50
50
  attr_accessor :competitor_rank
51
51
 
52
- # 100 times the weighted mean of the four similarities below, rounded to four places.
52
+ # The weighted share of the company's live target families that the competitor's live assets collide with, 0 to 100, rounded to four places. Each colliding family counts its best collision weight (rarity of the family across companies, times factors for same action, a shared indication, the least advanced stage, recency and a head-to-head trial), capped at the family's rarity weight; the sum is divided by the rarity weights of ALL the company's families.
53
53
  attr_accessor :competitor_score
54
54
 
55
- # Jaccard similarity, 0 to 1, of the two companies' molecular target sets.
56
- attr_accessor :target_sim
55
+ # Asset pairs (a drug of the company, a drug of the competitor) that act on a common target.
56
+ attr_accessor :n_collisions
57
57
 
58
- # Jaccard similarity, 0 to 1, of their mechanism sets (a target and its action).
59
- attr_accessor :mechanism_sim
58
+ # Target families of the company's live assets that the competitor collides with.
59
+ attr_accessor :n_colliding_families
60
60
 
61
- # Jaccard similarity, 0 to 1, of their top-25 disease area sets.
62
- attr_accessor :indication_sim
61
+ # Target families of the company's own live, owned assets; the denominator of competitor_score is their rarity weights.
62
+ attr_accessor :n_subject_families
63
63
 
64
- # The fraction, 0 to 1, of the shared targets that both companies have taken to phase 2 or later.
65
- attr_accessor :phase_sim
64
+ # Asset pairs whose drugs act on the shared target with the same action type.
65
+ attr_accessor :n_same_action
66
66
 
67
- # Molecular targets both companies pursue.
68
- attr_accessor :n_shared_targets
67
+ # Asset pairs whose programs share at least one disease area.
68
+ attr_accessor :n_shared_indication_pairs
69
69
 
70
- # Mechanisms (target and action) both companies pursue.
71
- attr_accessor :n_shared_mechanisms
70
+ # Distinct trials led by either company in which one drug of a pair is experimental and the other an active comparator.
71
+ attr_accessor :n_head_to_head_trials
72
72
 
73
- # Disease areas both companies are in, within each one's top 25.
74
- attr_accessor :n_shared_indications
75
-
76
- # Shared targets that both companies have taken to phase 2 or later.
77
- attr_accessor :n_phase_overlap_targets
78
-
79
- # Targets the company pursues (the Jaccard denominator).
80
- attr_accessor :n_company_targets
81
-
82
- # Targets the competitor pursues.
83
- attr_accessor :n_competitor_targets
84
-
85
- # Disease areas in the company's top 25.
86
- attr_accessor :n_company_indications
87
-
88
- # Disease areas in the competitor's top 25.
89
- attr_accessor :n_competitor_indications
90
-
91
- # Up to 5 shared target gene symbols, by combined phase then combined trials. An empty list when none.
92
- attr_accessor :top_shared_targets
93
-
94
- # Up to 5 shared disease area names, by combined trial count. An empty list when none.
95
- attr_accessor :top_shared_indications
96
-
97
- # Up to 3 shared mechanisms written as a gene symbol and an action, by combined phase then combined trials. An empty list when none.
98
- attr_accessor :top_shared_mechanisms
73
+ # Up to 3 strongest asset pairs as text: \"drug A / drug B: target family, stage, N shared indications\". The stage is the less advanced of the two programs. An ownership_basis of inferred_lead on the underlying pair (see company_asset_collisions) is an inference.
74
+ attr_accessor :top_collisions
99
75
 
100
76
  # Distinct trials on which the company and the competitor are both named as sponsors, counted over their subtrees; 0 when none. A consortium trial (more than 25 sponsor companies) is left out.
101
77
  attr_accessor :n_cosponsored_trials
@@ -115,21 +91,13 @@ module PharmaObservatory
115
91
  :'n_class_candidates' => :'n_class_candidates',
116
92
  :'competitor_rank' => :'competitor_rank',
117
93
  :'competitor_score' => :'competitor_score',
118
- :'target_sim' => :'target_sim',
119
- :'mechanism_sim' => :'mechanism_sim',
120
- :'indication_sim' => :'indication_sim',
121
- :'phase_sim' => :'phase_sim',
122
- :'n_shared_targets' => :'n_shared_targets',
123
- :'n_shared_mechanisms' => :'n_shared_mechanisms',
124
- :'n_shared_indications' => :'n_shared_indications',
125
- :'n_phase_overlap_targets' => :'n_phase_overlap_targets',
126
- :'n_company_targets' => :'n_company_targets',
127
- :'n_competitor_targets' => :'n_competitor_targets',
128
- :'n_company_indications' => :'n_company_indications',
129
- :'n_competitor_indications' => :'n_competitor_indications',
130
- :'top_shared_targets' => :'top_shared_targets',
131
- :'top_shared_indications' => :'top_shared_indications',
132
- :'top_shared_mechanisms' => :'top_shared_mechanisms',
94
+ :'n_collisions' => :'n_collisions',
95
+ :'n_colliding_families' => :'n_colliding_families',
96
+ :'n_subject_families' => :'n_subject_families',
97
+ :'n_same_action' => :'n_same_action',
98
+ :'n_shared_indication_pairs' => :'n_shared_indication_pairs',
99
+ :'n_head_to_head_trials' => :'n_head_to_head_trials',
100
+ :'top_collisions' => :'top_collisions',
133
101
  :'n_cosponsored_trials' => :'n_cosponsored_trials'
134
102
  }
135
103
  end
@@ -159,21 +127,13 @@ module PharmaObservatory
159
127
  :'n_class_candidates' => :'Integer',
160
128
  :'competitor_rank' => :'Integer',
161
129
  :'competitor_score' => :'Float',
162
- :'target_sim' => :'Float',
163
- :'mechanism_sim' => :'Float',
164
- :'indication_sim' => :'Float',
165
- :'phase_sim' => :'Float',
166
- :'n_shared_targets' => :'Integer',
167
- :'n_shared_mechanisms' => :'Integer',
168
- :'n_shared_indications' => :'Integer',
169
- :'n_phase_overlap_targets' => :'Integer',
170
- :'n_company_targets' => :'Integer',
171
- :'n_competitor_targets' => :'Integer',
172
- :'n_company_indications' => :'Integer',
173
- :'n_competitor_indications' => :'Integer',
174
- :'top_shared_targets' => :'Array<String>',
175
- :'top_shared_indications' => :'Array<String>',
176
- :'top_shared_mechanisms' => :'Array<String>',
130
+ :'n_collisions' => :'Integer',
131
+ :'n_colliding_families' => :'Integer',
132
+ :'n_subject_families' => :'Integer',
133
+ :'n_same_action' => :'Integer',
134
+ :'n_shared_indication_pairs' => :'Integer',
135
+ :'n_head_to_head_trials' => :'Integer',
136
+ :'top_collisions' => :'Array<String>',
177
137
  :'n_cosponsored_trials' => :'Integer'
178
138
  }
179
139
  end
@@ -193,21 +153,13 @@ module PharmaObservatory
193
153
  :'n_class_candidates',
194
154
  :'competitor_rank',
195
155
  :'competitor_score',
196
- :'target_sim',
197
- :'mechanism_sim',
198
- :'indication_sim',
199
- :'phase_sim',
200
- :'n_shared_targets',
201
- :'n_shared_mechanisms',
202
- :'n_shared_indications',
203
- :'n_phase_overlap_targets',
204
- :'n_company_targets',
205
- :'n_competitor_targets',
206
- :'n_company_indications',
207
- :'n_competitor_indications',
208
- :'top_shared_targets',
209
- :'top_shared_indications',
210
- :'top_shared_mechanisms',
156
+ :'n_collisions',
157
+ :'n_colliding_families',
158
+ :'n_subject_families',
159
+ :'n_same_action',
160
+ :'n_shared_indication_pairs',
161
+ :'n_head_to_head_trials',
162
+ :'top_collisions',
211
163
  :'n_cosponsored_trials'
212
164
  ])
213
165
  end
@@ -276,69 +228,33 @@ module PharmaObservatory
276
228
  self.competitor_score = attributes[:'competitor_score']
277
229
  end
278
230
 
279
- if attributes.key?(:'target_sim')
280
- self.target_sim = attributes[:'target_sim']
281
- end
282
-
283
- if attributes.key?(:'mechanism_sim')
284
- self.mechanism_sim = attributes[:'mechanism_sim']
285
- end
286
-
287
- if attributes.key?(:'indication_sim')
288
- self.indication_sim = attributes[:'indication_sim']
289
- end
290
-
291
- if attributes.key?(:'phase_sim')
292
- self.phase_sim = attributes[:'phase_sim']
293
- end
294
-
295
- if attributes.key?(:'n_shared_targets')
296
- self.n_shared_targets = attributes[:'n_shared_targets']
297
- end
298
-
299
- if attributes.key?(:'n_shared_mechanisms')
300
- self.n_shared_mechanisms = attributes[:'n_shared_mechanisms']
301
- end
302
-
303
- if attributes.key?(:'n_shared_indications')
304
- self.n_shared_indications = attributes[:'n_shared_indications']
231
+ if attributes.key?(:'n_collisions')
232
+ self.n_collisions = attributes[:'n_collisions']
305
233
  end
306
234
 
307
- if attributes.key?(:'n_phase_overlap_targets')
308
- self.n_phase_overlap_targets = attributes[:'n_phase_overlap_targets']
235
+ if attributes.key?(:'n_colliding_families')
236
+ self.n_colliding_families = attributes[:'n_colliding_families']
309
237
  end
310
238
 
311
- if attributes.key?(:'n_company_targets')
312
- self.n_company_targets = attributes[:'n_company_targets']
239
+ if attributes.key?(:'n_subject_families')
240
+ self.n_subject_families = attributes[:'n_subject_families']
313
241
  end
314
242
 
315
- if attributes.key?(:'n_competitor_targets')
316
- self.n_competitor_targets = attributes[:'n_competitor_targets']
243
+ if attributes.key?(:'n_same_action')
244
+ self.n_same_action = attributes[:'n_same_action']
317
245
  end
318
246
 
319
- if attributes.key?(:'n_company_indications')
320
- self.n_company_indications = attributes[:'n_company_indications']
247
+ if attributes.key?(:'n_shared_indication_pairs')
248
+ self.n_shared_indication_pairs = attributes[:'n_shared_indication_pairs']
321
249
  end
322
250
 
323
- if attributes.key?(:'n_competitor_indications')
324
- self.n_competitor_indications = attributes[:'n_competitor_indications']
325
- end
326
-
327
- if attributes.key?(:'top_shared_targets')
328
- if (value = attributes[:'top_shared_targets']).is_a?(Array)
329
- self.top_shared_targets = value
330
- end
331
- end
332
-
333
- if attributes.key?(:'top_shared_indications')
334
- if (value = attributes[:'top_shared_indications']).is_a?(Array)
335
- self.top_shared_indications = value
336
- end
251
+ if attributes.key?(:'n_head_to_head_trials')
252
+ self.n_head_to_head_trials = attributes[:'n_head_to_head_trials']
337
253
  end
338
254
 
339
- if attributes.key?(:'top_shared_mechanisms')
340
- if (value = attributes[:'top_shared_mechanisms']).is_a?(Array)
341
- self.top_shared_mechanisms = value
255
+ if attributes.key?(:'top_collisions')
256
+ if (value = attributes[:'top_collisions']).is_a?(Array)
257
+ self.top_collisions = value
342
258
  end
343
259
  end
344
260
 
@@ -379,21 +295,13 @@ module PharmaObservatory
379
295
  n_class_candidates == o.n_class_candidates &&
380
296
  competitor_rank == o.competitor_rank &&
381
297
  competitor_score == o.competitor_score &&
382
- target_sim == o.target_sim &&
383
- mechanism_sim == o.mechanism_sim &&
384
- indication_sim == o.indication_sim &&
385
- phase_sim == o.phase_sim &&
386
- n_shared_targets == o.n_shared_targets &&
387
- n_shared_mechanisms == o.n_shared_mechanisms &&
388
- n_shared_indications == o.n_shared_indications &&
389
- n_phase_overlap_targets == o.n_phase_overlap_targets &&
390
- n_company_targets == o.n_company_targets &&
391
- n_competitor_targets == o.n_competitor_targets &&
392
- n_company_indications == o.n_company_indications &&
393
- n_competitor_indications == o.n_competitor_indications &&
394
- top_shared_targets == o.top_shared_targets &&
395
- top_shared_indications == o.top_shared_indications &&
396
- top_shared_mechanisms == o.top_shared_mechanisms &&
298
+ n_collisions == o.n_collisions &&
299
+ n_colliding_families == o.n_colliding_families &&
300
+ n_subject_families == o.n_subject_families &&
301
+ n_same_action == o.n_same_action &&
302
+ n_shared_indication_pairs == o.n_shared_indication_pairs &&
303
+ n_head_to_head_trials == o.n_head_to_head_trials &&
304
+ top_collisions == o.top_collisions &&
397
305
  n_cosponsored_trials == o.n_cosponsored_trials
398
306
  end
399
307
 
@@ -406,7 +314,7 @@ module PharmaObservatory
406
314
  # Calculates hash code according to all attributes.
407
315
  # @return [Integer] Hash code
408
316
  def hash
409
- [company_id, company_name, group_id, group_name, competitor_company_id, competitor_company_name, competitor_group_id, competitor_group_name, competitor_class, n_class_candidates, competitor_rank, competitor_score, target_sim, mechanism_sim, indication_sim, phase_sim, n_shared_targets, n_shared_mechanisms, n_shared_indications, n_phase_overlap_targets, n_company_targets, n_competitor_targets, n_company_indications, n_competitor_indications, top_shared_targets, top_shared_indications, top_shared_mechanisms, n_cosponsored_trials].hash
317
+ [company_id, company_name, group_id, group_name, competitor_company_id, competitor_company_name, competitor_group_id, competitor_group_name, competitor_class, n_class_candidates, competitor_rank, competitor_score, n_collisions, n_colliding_families, n_subject_families, n_same_action, n_shared_indication_pairs, n_head_to_head_trials, top_collisions, n_cosponsored_trials].hash
410
318
  end
411
319
 
412
320
  # Builds the object from hash
@@ -61,6 +61,33 @@ module PharmaObservatory
61
61
  # The latest fiscal year the filer reported any line item.
62
62
  attr_accessor :latest_financial_fy
63
63
 
64
+ # The end of the latest reported quarter of the filer that has an operating cash flow figure (a 10-Q, or the Q4 derived from a 10-K); the date of the cash figure below. Repeated on every year row of the filer; null for a company with no quarterly SEC filings.
65
+ attr_accessor :quarter_end_date
66
+
67
+ # The date SEC received the filing of that latest quarter.
68
+ attr_accessor :quarter_filed_date
69
+
70
+ # Cash plus short-term investments at quarter_end_date, in USD (non-current investments are not counted).
71
+ attr_accessor :cash_and_investments_latest_q
72
+
73
+ # Net cash from operating activities of that latest quarter alone (year-to-date figures differenced; Q4 is the full year less nine months), in USD; negative means burning.
74
+ attr_accessor :operating_cash_flow_latest_q
75
+
76
+ # How many contiguous quarters burn_basis_quarterly_usd averages over, 1 or 2.
77
+ attr_accessor :burn_basis_quarters
78
+
79
+ # The mean quarterly operating cash flow over the latest two contiguous quarters (the latest alone when no contiguous earlier quarter has a figure), in USD; negative means burning.
80
+ attr_accessor :burn_basis_quarterly_usd
81
+
82
+ # An estimate, derived not reported: cash_and_investments_latest_q divided by the monthly burn (burn_basis_quarterly_usd over 3), in months at quarter_end_date, rounded to 0.1. Null whenever runway_quarterly_null_reason is set.
83
+ attr_accessor :runway_months_quarterly
84
+
85
+ # The version of the derivation behind runway_months_quarterly; trailing_quarter_mean_v1 is the mean of the latest two contiguous discrete quarters.
86
+ attr_accessor :runway_quarterly_method
87
+
88
+ # Why runway_months_quarterly is null, in precedence order: no_quarterly_facts (no 10-Q cash-flow facts: a private company or a 20-F/40-F filer), stale (the latest quarter ended over a year before the newest SEC filing loaded), no_fx_rate, no_cash_at_quarter_end, or positive_cash_flow (no burn to run out of). Null when the runway is published.
89
+ attr_accessor :runway_quarterly_null_reason
90
+
64
91
  # Total revenue for the fiscal year, in USD (a non-USD filer is converted at the calendar-year average rate; null when no rate exists).
65
92
  attr_accessor :revenue
66
93
 
@@ -172,6 +199,15 @@ module PharmaObservatory
172
199
  :'latest_shares_outstanding' => :'latest_shares_outstanding',
173
200
  :'latest_shares_outstanding_fy' => :'latest_shares_outstanding_fy',
174
201
  :'latest_financial_fy' => :'latest_financial_fy',
202
+ :'quarter_end_date' => :'quarter_end_date',
203
+ :'quarter_filed_date' => :'quarter_filed_date',
204
+ :'cash_and_investments_latest_q' => :'cash_and_investments_latest_q',
205
+ :'operating_cash_flow_latest_q' => :'operating_cash_flow_latest_q',
206
+ :'burn_basis_quarters' => :'burn_basis_quarters',
207
+ :'burn_basis_quarterly_usd' => :'burn_basis_quarterly_usd',
208
+ :'runway_months_quarterly' => :'runway_months_quarterly',
209
+ :'runway_quarterly_method' => :'runway_quarterly_method',
210
+ :'runway_quarterly_null_reason' => :'runway_quarterly_null_reason',
175
211
  :'revenue' => :'revenue',
176
212
  :'net_income' => :'net_income',
177
213
  :'rnd' => :'rnd',
@@ -234,6 +270,15 @@ module PharmaObservatory
234
270
  :'latest_shares_outstanding' => :'Float',
235
271
  :'latest_shares_outstanding_fy' => :'Integer',
236
272
  :'latest_financial_fy' => :'Integer',
273
+ :'quarter_end_date' => :'Date',
274
+ :'quarter_filed_date' => :'Date',
275
+ :'cash_and_investments_latest_q' => :'Float',
276
+ :'operating_cash_flow_latest_q' => :'Float',
277
+ :'burn_basis_quarters' => :'Integer',
278
+ :'burn_basis_quarterly_usd' => :'Float',
279
+ :'runway_months_quarterly' => :'Float',
280
+ :'runway_quarterly_method' => :'String',
281
+ :'runway_quarterly_null_reason' => :'String',
237
282
  :'revenue' => :'Float',
238
283
  :'net_income' => :'Float',
239
284
  :'rnd' => :'Float',
@@ -286,6 +331,15 @@ module PharmaObservatory
286
331
  :'latest_shares_outstanding',
287
332
  :'latest_shares_outstanding_fy',
288
333
  :'latest_financial_fy',
334
+ :'quarter_end_date',
335
+ :'quarter_filed_date',
336
+ :'cash_and_investments_latest_q',
337
+ :'operating_cash_flow_latest_q',
338
+ :'burn_basis_quarters',
339
+ :'burn_basis_quarterly_usd',
340
+ :'runway_months_quarterly',
341
+ :'runway_quarterly_method',
342
+ :'runway_quarterly_null_reason',
289
343
  :'revenue',
290
344
  :'net_income',
291
345
  :'rnd',
@@ -396,6 +450,42 @@ module PharmaObservatory
396
450
  self.latest_financial_fy = attributes[:'latest_financial_fy']
397
451
  end
398
452
 
453
+ if attributes.key?(:'quarter_end_date')
454
+ self.quarter_end_date = attributes[:'quarter_end_date']
455
+ end
456
+
457
+ if attributes.key?(:'quarter_filed_date')
458
+ self.quarter_filed_date = attributes[:'quarter_filed_date']
459
+ end
460
+
461
+ if attributes.key?(:'cash_and_investments_latest_q')
462
+ self.cash_and_investments_latest_q = attributes[:'cash_and_investments_latest_q']
463
+ end
464
+
465
+ if attributes.key?(:'operating_cash_flow_latest_q')
466
+ self.operating_cash_flow_latest_q = attributes[:'operating_cash_flow_latest_q']
467
+ end
468
+
469
+ if attributes.key?(:'burn_basis_quarters')
470
+ self.burn_basis_quarters = attributes[:'burn_basis_quarters']
471
+ end
472
+
473
+ if attributes.key?(:'burn_basis_quarterly_usd')
474
+ self.burn_basis_quarterly_usd = attributes[:'burn_basis_quarterly_usd']
475
+ end
476
+
477
+ if attributes.key?(:'runway_months_quarterly')
478
+ self.runway_months_quarterly = attributes[:'runway_months_quarterly']
479
+ end
480
+
481
+ if attributes.key?(:'runway_quarterly_method')
482
+ self.runway_quarterly_method = attributes[:'runway_quarterly_method']
483
+ end
484
+
485
+ if attributes.key?(:'runway_quarterly_null_reason')
486
+ self.runway_quarterly_null_reason = attributes[:'runway_quarterly_null_reason']
487
+ end
488
+
399
489
  if attributes.key?(:'revenue')
400
490
  self.revenue = attributes[:'revenue']
401
491
  end
@@ -556,6 +646,15 @@ module PharmaObservatory
556
646
  latest_shares_outstanding == o.latest_shares_outstanding &&
557
647
  latest_shares_outstanding_fy == o.latest_shares_outstanding_fy &&
558
648
  latest_financial_fy == o.latest_financial_fy &&
649
+ quarter_end_date == o.quarter_end_date &&
650
+ quarter_filed_date == o.quarter_filed_date &&
651
+ cash_and_investments_latest_q == o.cash_and_investments_latest_q &&
652
+ operating_cash_flow_latest_q == o.operating_cash_flow_latest_q &&
653
+ burn_basis_quarters == o.burn_basis_quarters &&
654
+ burn_basis_quarterly_usd == o.burn_basis_quarterly_usd &&
655
+ runway_months_quarterly == o.runway_months_quarterly &&
656
+ runway_quarterly_method == o.runway_quarterly_method &&
657
+ runway_quarterly_null_reason == o.runway_quarterly_null_reason &&
559
658
  revenue == o.revenue &&
560
659
  net_income == o.net_income &&
561
660
  rnd == o.rnd &&
@@ -598,7 +697,7 @@ module PharmaObservatory
598
697
  # Calculates hash code according to all attributes.
599
698
  # @return [Integer] Hash code
600
699
  def hash
601
- [company_id, company_name, group_id, group_name, reporting_org_id, fiscal_year, is_public, edgar_cik, ticker, exchange, public_float_usd, public_float_fy, latest_shares_outstanding, latest_shares_outstanding_fy, latest_financial_fy, revenue, net_income, rnd, assets, equity, public_float, cash, short_term_investments, cash_and_investments, operating_cash_flow, shares_outstanding, stock_based_compensation, operating_expenses, dividends_paid, eps_basic, eps_diluted, total_liabilities, long_term_debt_noncurrent, long_term_debt_total, intangible_assets, property_plant_equipment, goodwill, inventory, accounts_payable, accounts_receivable, weighted_average_shares_basic, weighted_average_shares_diluted, burn_basis_usd, burn_basis_years, runway_months, sec_total_revenue_usd_millions].hash
700
+ [company_id, company_name, group_id, group_name, reporting_org_id, fiscal_year, is_public, edgar_cik, ticker, exchange, public_float_usd, public_float_fy, latest_shares_outstanding, latest_shares_outstanding_fy, latest_financial_fy, quarter_end_date, quarter_filed_date, cash_and_investments_latest_q, operating_cash_flow_latest_q, burn_basis_quarters, burn_basis_quarterly_usd, runway_months_quarterly, runway_quarterly_method, runway_quarterly_null_reason, revenue, net_income, rnd, assets, equity, public_float, cash, short_term_investments, cash_and_investments, operating_cash_flow, shares_outstanding, stock_based_compensation, operating_expenses, dividends_paid, eps_basic, eps_diluted, total_liabilities, long_term_debt_noncurrent, long_term_debt_total, intangible_assets, property_plant_equipment, goodwill, inventory, accounts_payable, accounts_receivable, weighted_average_shares_basic, weighted_average_shares_diluted, burn_basis_usd, burn_basis_years, runway_months, sec_total_revenue_usd_millions].hash
602
701
  end
603
702
 
604
703
  # Builds the object from hash
@@ -28,13 +28,21 @@ module PharmaObservatory
28
28
  # Trials for this condition that report the term.
29
29
  attr_accessor :n_trials
30
30
 
31
+ # Distinct serious adverse event terms across the condition's trials. The rows are only the top 10 of these, so a row count is not the term count; use this.
32
+ attr_accessor :n_terms_total
33
+
34
+ # Results-posting trials of the condition that report at least one serious adverse event term.
35
+ attr_accessor :n_trials_total
36
+
31
37
  # Attribute mapping from ruby-style variable name to JSON key.
32
38
  def self.attribute_map
33
39
  {
34
40
  :'condition_id' => :'condition_id',
35
41
  :'adverse_event_term' => :'adverse_event_term',
36
42
  :'subjects_affected' => :'subjects_affected',
37
- :'n_trials' => :'n_trials'
43
+ :'n_trials' => :'n_trials',
44
+ :'n_terms_total' => :'n_terms_total',
45
+ :'n_trials_total' => :'n_trials_total'
38
46
  }
39
47
  end
40
48
 
@@ -54,7 +62,9 @@ module PharmaObservatory
54
62
  :'condition_id' => :'String',
55
63
  :'adverse_event_term' => :'String',
56
64
  :'subjects_affected' => :'Float',
57
- :'n_trials' => :'Integer'
65
+ :'n_trials' => :'Integer',
66
+ :'n_terms_total' => :'Integer',
67
+ :'n_trials_total' => :'Integer'
58
68
  }
59
69
  end
60
70
 
@@ -64,7 +74,9 @@ module PharmaObservatory
64
74
  :'condition_id',
65
75
  :'adverse_event_term',
66
76
  :'subjects_affected',
67
- :'n_trials'
77
+ :'n_trials',
78
+ :'n_terms_total',
79
+ :'n_trials_total'
68
80
  ])
69
81
  end
70
82
 
@@ -99,6 +111,14 @@ module PharmaObservatory
99
111
  if attributes.key?(:'n_trials')
100
112
  self.n_trials = attributes[:'n_trials']
101
113
  end
114
+
115
+ if attributes.key?(:'n_terms_total')
116
+ self.n_terms_total = attributes[:'n_terms_total']
117
+ end
118
+
119
+ if attributes.key?(:'n_trials_total')
120
+ self.n_trials_total = attributes[:'n_trials_total']
121
+ end
102
122
  end
103
123
 
104
124
  # Show invalid properties with the reasons. Usually used together with valid?
@@ -124,7 +144,9 @@ module PharmaObservatory
124
144
  condition_id == o.condition_id &&
125
145
  adverse_event_term == o.adverse_event_term &&
126
146
  subjects_affected == o.subjects_affected &&
127
- n_trials == o.n_trials
147
+ n_trials == o.n_trials &&
148
+ n_terms_total == o.n_terms_total &&
149
+ n_trials_total == o.n_trials_total
128
150
  end
129
151
 
130
152
  # @see the `==` method
@@ -136,7 +158,7 @@ module PharmaObservatory
136
158
  # Calculates hash code according to all attributes.
137
159
  # @return [Integer] Hash code
138
160
  def hash
139
- [condition_id, adverse_event_term, subjects_affected, n_trials].hash
161
+ [condition_id, adverse_event_term, subjects_affected, n_trials, n_terms_total, n_trials_total].hash
140
162
  end
141
163
 
142
164
  # Builds the object from hash